|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
List of Ongoing Clinical Trials: Patient Summary
CALGB 40101
Cyclophosphamide and Doxorubicin Versus Paclitaxel as
Adjuvant Therapy for Women
with 0-3 Positive Axillary Lymph Nodes: A 2 × 2 Factorial Phase III Randomized
Study
Summary
Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and paclitaxel,
work in different ways to stop tumor cells from dividing so they stop growing
or die. Combining more than one drug may kill more tumor cells. It is no
yet known whether giving cyclophosphamide together with doxorubicin is more
effective than giving paclitaxel alone in treating breast cancer.
This randomized phase III trial is studying cyclophosphamide and doxorubicin to see how well they work compared to paclitaxel in treating women with invasive breast cancer.
Consent Form for Patients | Fast Fact Sheet